Novartis/HGS’ Albuferon May Offer Dosing Advantages Over Roche’s Pegasys
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III program for the chronic hepatitis C treatment includes two non-inferiority trials comparing once-weekly Pegasys to bi-weekly Albuferon.